A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01756495 |
Recruitment Status
:
Completed
First Posted
: December 27, 2012
Last Update Posted
: June 7, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Coronary Syndrome | Drug: Losmapimod Drug: Moxifloxacin Drug: Losmapimod matched Placebo Drug: Moxifloxacin Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 56 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects |
Actual Study Start Date : | January 10, 2013 |
Actual Primary Completion Date : | April 23, 2013 |
Actual Study Completion Date : | April 23, 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Losmapimod 7.5 mg
Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
|
Drug: Losmapimod
Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
|
Experimental: Losmapimod 20 mg
Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
|
Drug: Losmapimod
Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
|
Active Comparator: Moxifloxacin 400 mg
Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
|
Drug: Moxifloxacin
17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
|
Placebo Comparator: Placebo
Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
|
Drug: Losmapimod matched Placebo
Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
Drug: Moxifloxacin Placebo
16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
|
- Change from baseline in QT interval corrected for heart rate by Fridericia's formula (QTcF) at each time point for losmapimod 20 mg QD on Day 5 as compared with time matched placebo [ Time Frame: Baseline and Day 5 of the corresponding study period ]Triplicate ECGs will be collected at three baseline pre-dose time points (at -45 min, -30 min and -15 min) on Day 1 of the corresponding study period. Period baseline will be the average of triplicate pre-dose assessments. Triplicate Holter ECGs measurements will be evaluated at 14 post-dose time points (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours) on Day 5 of the corresponding study period and will be averaged prior to calculation of changes from period baseline and statistical analyses
- Change from baseline in QTcF at each time point for losmapimod 7.5 mg BID on Day 5 as compared with time-matched placebo [ Time Frame: Baseline and Day 5 of the corresponding study period ]Triplicate ECGs will be collected at three baseline pre-dose time points (at -45 min, -30 min and -15 min) on Day 1 of the corresponding study period. Period baseline will be the average of triplicate pre-dose assessments. Triplicate Holter ECGs measurements will be evaluated at 14 post-dose time points (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours) on Day 5 of the corresponding study period and will be averaged prior to calculation of changes from period baseline and statistical analyses
- Change from baseline in QTcF at each time point for moxifloxacin 400 mg single dose as compared with time-matched placebo [ Time Frame: Baseline and Day 5 of the corresponding study period ]Triplicate ECGs will be collected at three baseline pre-dose time points (at -45 min, -30 min and -15 min) on Day 1 of the corresponding study period. Period baseline will be the average of triplicate pre-dose assessments. Triplicate Holter ECGs measurements will be evaluated at 14 post-dose time points (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours) on Day 5 of the corresponding study period and will be averaged prior to calculation of changes from period baseline and statistical analyses
- Change from baseline in QT interval corrected for heart rate by Bazett's formula (QTcB) at each time point for losmapimod (7.5 mg BID and 20 mg QD) and moxifloxacin (400 mg) on Day 5 as compared with time matched placebo [ Time Frame: Baseline and Day 5 of all 4 study period ]Triplicate ECGs will be collected at three baseline pre-dose time points (at 45 min, -30 min and -15 min) on Day 1 of all study periods. Period Baseline will be the average of triplicate pre-dose assessments. Triplicate Holter ECGs measurements will be evaluated at 14 post-dose time points (0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and 24 hours) on Day 5 of all the study period and will be averaged prior to calculation of changes from period baseline and statistical analyses
- Change from baseline at each time point on Day 5 for other cardiac electrophysiological parameters: QT, PR, QRS, heart rate (HR) and ECG waveform morphology for losmapimod (7.5 mg BID and 20 mg QD) and moxifloxacin [ Time Frame: Baseline and Day 5 of all 4 study period ]Single 12-lead ECG that automatically calculates the heart rate and measures PR, QRS, QT will be taken at 0, 2, 4 and 6 hour time points
- Area under the plasma concentration-time curve (AUC) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin [ Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and approximately 24 hours post-dose on Day 5 of all 4 study period ]Pharmacokinetics (PK )Trough samples will be collected pre-dose on Days 3 and 4 of each period
- Maximum observed plasma concentration (Cmax) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin [ Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and approximately 24 hours post-dose on Day 5 of all 4 study period ]PK Trough samples will be collected pre-dose on Days 3 and 4 of each period
- Time to Cmax (Tmax) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin [ Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18 and approximately 24 hours post-dose on Day 5 of all 4 study period ]PK Trough samples will be collected pre-dose on Days 3 and 4 of each period
- Model parameters appropriate for concentration-QT analysis of losmapimod, metabolite and moxifloxacin (e.g. slope and intercept) [ Time Frame: Day 5 of all 4 study period ]The relationship between losmapimod as well as GSK198602 plasma concentrations following repeat oral administration and the time-matched drug-placebo difference in QTc interval (∆∆QTc) will be explored graphically. If an apparent concentration-effect relationship exists, a population PK/ (pharmacodynamics) PD model will be established using nonlinear mixed effects modeling techniques with NONMEM software
- Physical examination findings to assess safety and tolerability of losmapimod and moxifloxacin [ Time Frame: Up to Day 49 ]A complete physical examination (of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen [liver and spleen], lymph nodes and extremities, height and weight) will occur at the screening and follow up visits. A brief physical examination (of the skin, lungs, cardiovascular system, and abdomen [liver and spleen]) will occur at Day -1
- 12-lead ECGs measurements to assess safety and tolerability of losmapimod and moxifloxacin [ Time Frame: Up to Day 49 ]As part of safety assessments, single 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals
- Clinical laboratory test measurements to assess safety and tolerability of losmapimod and moxifloxacin [ Time Frame: Up to Day 49 ]Samples will be collected at Screening, Day -1, follow-up for assessing safety
- Clinical monitoring/observation [ Time Frame: Up to Day 49 ]The safety and tolerability of repeat oral doses of losmapimod 20mg QD and 7.5mg BID, as well as a single dose of moxifloxacin
- Number of subjects with adverse events [ Time Frame: Up to Day 49 ]The safety and tolerability will be assessed by adverse events (AEs) of repeat oral doses of losmapimod 20mg QD and 7.5mg BID, as well as a single dose of moxifloxacin
- Blood pressure measurements to assess safety and tolerability of losmapimod and moxifloxacin [ Time Frame: Up to Day 49 ]One measurement of blood pressure will be taken at Screening, Day -1 and Follow Up at the 0 hour timepoint on Day -1 and Follow up. Blood pressure measurement will be taken at 0, 2, 4 and 6 hour time points on Days 1, 4 and 5
- HR measurements to assess safety and tolerability of losmapimod and moxifloxacin [ Time Frame: Up to Day 49 ]One measurement of HR will be taken at Screening, Day -1 and Follow Up at the 0 hour timepoint on Day -1 and Follow up. HR measurement will be taken at 0, 2, 4 and 6 hour time points on Days 1, 4 and 5

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac safety monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent
-
A female subject is eligible to participate if she is of
- Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] >40 MIU/mL and estradiol <40 pg/mL [<147 pmol/L] is confirmatory)
- Child-bearing potential and is abstinent or agrees to use one of the allowed contraception methods with a failure rate of <1% (Oral contraceptive, either combined or progestogen alone, Injectable progestogen, Implants of etonogestrel or levonorgestrel, Estrogenic vaginal ring, Percutaneous contraceptive patches, Intrauterine device [IUD] or intrauterine system [IUS], Male partner sterilization [vasectomy with documentation of azoospermia] prior to the female subject's entry into the study, and this male is the sole partner for that subject, Male condom combined with a female diaphragm, either with or without a vaginal spermicide [foam, gel, cream or suppository], Male condom combined with a vaginal spermicide [foam, gel, cream or suppository]) for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit
- Body weight >=50 kg and Body mass index (BMI) within the range 19 to 28 kg/m^2 (inclusive)
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5 x upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
Exclusion Criteria:
-
Subjects with cardiac conduction abnormalities on the screening 12-lead ECG denoted by any of the following
- QTcB or QTcF >450 msec
- PR interval >200 msec or <=110 msec
- evidence of second- or third- degree atrioventricular block (AVB)
- clinically significant pathological Q-waves (defined as Q-wave >40 msec or depth greater than 0.4 to 0.5 mV)
- evidence of ventricular pre-excitation
- electrocardiographic evidence of complete left bundle branch block (LBBB), right bundle branch block (RBBB), incomplete LBBB
- intraventricular conduction delay with QRS duration >110 msec
- bradycardia as defined by sinus rate <45 beats per minute (BPM) or tachycardia as defined by sinus rate >100 BPM
- Any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or ECG
- Subjects with a personal or family history of QTc prolongation, symptomatic cardiac arrhythmias or cardiac arrest
- History of hypersensitivity to moxifloxacin or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen
- A positive test for Human immunodeficiency virus (HIV) antibody result within 3 months of screening
- History of regular alcohol consumption within 6 months of the study defined as (For US sites) an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
- Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) test at screening or prior to dosing
- Lactating females
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated
- History of sensitivity to heparin or heparin-induced thrombocytopenia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01756495
United States, Maryland | |
GSK Investigational Site | |
Baltimore, Maryland, United States, 21225 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Additional Information:
Study Data/Documents: Study Protocol

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register

For additional information about this study please refer to the GSK Clinical Study Register
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01756495 History of Changes |
Other Study ID Numbers: |
116628 |
First Posted: | December 27, 2012 Key Record Dates |
Last Update Posted: | June 7, 2017 |
Last Verified: | June 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site. |
Keywords provided by GlaxoSmithKline:
QTc, GW856553 . P38, |
Additional relevant MeSH terms:
Acute Coronary Syndrome Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Moxifloxacin Fluoroquinolones Norgestimate, ethinyl estradiol drug combination Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors |
Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Contraceptives, Oral, Combined Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Nucleic Acid Synthesis Inhibitors |